FDA notes at CDC advisory committee meeting that it has a Moderna submission for #covid19 vaccine booster, and “we are working diligently to get that completed.”
FDA says it’s working with partners including NIH to provide a solution about boosters for all - “I don’t know if I can provide a specific timeframe,” Dr Doran Fink says.
Dr Peter Marks joins: “We understand at FDA the relative urgency here of trying to have a solution for anyone who’s been vaccinated with any of the authorized or approved vaccines. Unfortunately we’re not in a place right now where I can give you an exact timeline… (cont)
Marks: “…but we’ll proceed with all due urgency to get there as rapidly as possible working with the various vaccine sponsors and available data to make a science-based decision.”
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I just spoke with Dr Katherine Poehling from Wake Forest, one of the CDC advisory cmte members whose vote was ostensibly overruled by @CDCDirector Dr Rochelle Walensky on Pfizer #covid19 booster.
I say ostensibly, because Dr Poehling says she feels like Dr Walensky listened. (1)
ACIP member Dr Poehling:
“We’re an advisory committee, and I felt like our perspectives were clearly heard. And so I felt like the process actually worked well.” (2)
Dr Poehling says she voted no because she was concerned people in that last category (at occupational/setting risk) would feel they didn’t have a choice BUT to get a booster.
But Dr Walensky's recommendation added the word "may" for that category. (3)
FDA booster meeting Q&A begins w Dr Marion Gruber turning it over to Dr Phil Krause, who notes much of the data being discussed today is "not peer-reviewed and has not been reviewed by FDA."
Asks Pfizer whether Kaiser model accurately reflects true vaccine effectiveness
Dr Krause highly critical of Kaiser study supporting Pfizer conclusions
And Pfizer is having crazy audio issues responding to Dr Krause
Agenda posted for FDA advisory committee meeting Friday on #covid19 boosters. Departing regulator Dr Marion Gruber kicks off the morning with an introduction of the topic (after this week co-authoring letter saying boosters not needed): fda.gov/media/152159/d…
Also interesting, on FDA’s agenda for Friday booster shot advisory mtg: presenters from UK & Israel on real-world evidence
In its briefing docs for Friday’s FDA booster mtg, Pfizer lays out the case for boosting at 6-8 months, citing data from Israel & US. Notes the erosion is likely due more to waning effectiveness than Delta escape: fda.gov/media/152161/d…
Moderna says its vaccine shows durable 93% efficacy through 6 months, says it expects to complete FDA submission for full approval this month: investors.modernatx.com/news-releases/…
Pfizer research chief on quarterly earnings conf call just now: "We continue to believe it is likely that a third dose may be needed within six to 12 months of the full vaccination to maintain the highest level of protection." #covid19
Pfizer has contracts for 2.1B #covid19 vaccine doses in 2021, and plans to make 3B this year. CEO says on conf call just now co is in advanced discussions for many of the remaining doses and expects they'll all be allocated. Capacity for 2022 expected to be 4B doses.
Bernstein's Ronny Gal predicts an additional ~$10B in 2021 revenue for remaining #covid19 vaccine doses not yet contracted. Would mean $43.5B in total 2021 revenue from the Covid vaccine.